Navigation Links
Study: Resiniferatoxin may increase sepsis-related mortality
Date:4/27/2011

Washington, DC Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.

The study, which appears in the May 1 edition of the journal Anesthesiology, sheds new light on the role of a pain receptor, transient receptor potential vanilloid-1 (TRPV1), and how medications designed to impact this receptor's relay of the pain sensation to the brain might work in humans.

Scientists, led by Zenaide Quezado, MD, director of the Pain Neurobiology Laboratory of the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National, studied in animal models the effects of two different medications, resiniferatoxin and capsazepine, that are known to impact TRPV1, an ion receptor channel that signals sharp, painful stimuli to the brain, and triggers a pain response. These drugs block the activation of the TRPV1 receptor in different ways. For example, resiniferatoxin binds to the TRPV1 receptor and as a result opens calcium channels and ultimately destroys the nerves that have the receptor. The team discovered that, in the case of resiniferatoxin, the chemical reaction also negatively impacts the body's reaction to bacterial infections by altering cytokine and chemokine expression, signaling molecules which are key to the natural immune response to bacteria.

Resiniferatoxin shows great promise to ease chronic pain by targeting that pain in an entirely new way. If successful, it may allow patients who suffer from long-term diseases and who cannot benefit from traditional pain management medications, respite. As a result, the National Institutes of Health are undertaking a series of clinical trials in humans to determine its effectiveness.

"Our job as pain medicine researchers is to try and uncover as much about these medications and side effects as possible so that we can monitor and treat those side effects," said Dr. Quezado, senior author of the study and a pediatric anesthesiologist. "This study alerts us to a possible side effect of resiniferatoxin that might impact when and how the drug is used. However, for many patients, the chance to finally ease long term pain caused by diseases such as cancer may outweigh a risk that the medication may impact their body's ability to heal from bacterial infection."


'/>"/>

Contact: Jennifer Stinebiser
jstinebi@childrensnational.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related medicine news :

1. New study: Health reform to make health insurance affordable for nearly all families
2. Study: Parents likely to embrace predictive genetic testing for their children if offered
3. Study: Socioeconomics playing reduced role in autism diagnoses
4. STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss
5. Long-term study: Robot-assisted prostate surgery is safe
6. Study: Infrequent Sex Can Raise Risk of Heart Attack, Death
7. Study: Reluctance to Speak Up Encourages Medical Errors
8. IU study: Smoke-free air law had no effect on off-track betting facility business activity
9. Study: Multi-tasking on the street not a good idea for older people
10. Study: Lack of Vitamin D May Precede Onset of Parkinsons
11. UTHealth study: Stem cells may provide treatment for brain injuries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a leading provider ... magazine has named the company a “Top 25 Cybersecurity Companies 2017.” Axiad ... help organizations simply and proactively address potential cybersecurity threats before they happen. The ...
(Date:5/23/2017)... ... 23, 2017 , ... PM360, the premier information resource for ... winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders • ... industry today. , Out of more than 500 submissions, 100 winners were selected ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of ... Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on Health & Human ... the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released ...
(Date:5/23/2017)... ... 23, 2017 , ... The National Council on Strength and ... the organization’s Certified Strength Coach credential has earned accreditation from the National Commission ... the competency of qualified candidates for jobs in the Strength and Conditioning profession. ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment option called ... elastin in their face, neck, and body through a virtually pain-free, non-surgical treatment. ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/10/2017)... -- The Corporate Whistleblower Center says, "We are urging ... to call us anytime at 866-714-6466 if they possess ... a substantial scheme to overbill Medicare. We are ... of a medical equipment company if their employer ... practice groups with extra generous incentives to use, or ...
Breaking Medicine Technology: